The talk will explore approaches to speed up the discovery of chimeric antigen receptor (CAR), including methods for identifying tumor-associated antigen (TAA) antibodies in formats like single domain antibodies (VHHs) or single chain variable fragments (scFvs). It will also discuss proof-of-concept testing of CAR leads using in vivo assays and animal models. Attendees will gain insights into cutting-edge technologies to optimize CAR design, and enhanced functionality leading to improved expression, reduced toxicities, and improved efficacy.
